AIA Group Ltd cut its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 10.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 79,196 shares of the biopharmaceutical company’s stock after selling 8,842 shares during the quarter. AIA Group Ltd’s holdings in Pfizer were worth $2,280,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Worth Asset Management LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $30,000. Sanctuary Wealth Management L.L.C. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $50,000. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer during the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.
Pfizer Price Performance
Shares of PFE stock opened at $25.41 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37. The company has a market cap of $143.89 billion, a P/E ratio of 70.51, a P/E/G ratio of 1.15 and a beta of 0.61. The business has a fifty day simple moving average of $27.14 and a 200 day simple moving average of $28.74.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on PFE shares. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $36.88.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- What is the Dogs of the Dow Strategy? Overview and Examples
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
- What is the Australian Securities Exchange (ASX)
- Salesforce Stock Analysis: Deep Dive into CRM Market Performance
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.